NCT06930976 Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
| NCT ID | NCT06930976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Glucose |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2025-10-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 or older Exclusion Criteria: * Pregnant * Prisoner or in police custody * Uncontrolled hyperglycemia/diabetes * Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period * Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives * Any reason which, in the opinion of the study investigator, adds additional risk to the participant
Contact & Investigator
Matthew T Stier, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
Vanderbilt University Medical Center
Frequently Asked Questions
Who can join the NCT06930976 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glucose. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06930976 currently recruiting?
Yes, NCT06930976 is actively recruiting participants. Contact the research team at matthew.stier@vumc.org for enrollment information.
Where is the NCT06930976 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06930976 clinical trial?
NCT06930976 is sponsored by Vanderbilt University Medical Center. The principal investigator is Matthew T Stier, M.D., Ph.D. at Vanderbilt University Medical Center. The trial plans to enroll 12 participants.